Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06337695
Other study ID # HREBA.CC-23-0271
Secondary ID
Status Not yet recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date July 1, 2024
Est. completion date December 1, 2026

Study information

Verified date October 2023
Source University of Calgary
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the prevention of immune checkpoint inhibitors (ICIs) related diarrhea/colitis using vedolizumab in participants with unresectable stage III or metastatic stage IV cancer, starting standard of care (SOC) immunotherapy


Description:

After being informed about the study and potential risks, all patients giving written informed consent will undergo up to a 2-week screening period to confirm their eligibility. Eligible patients will be randomized in a double-blind manner (participant and investigator) in a 1:1 ratio to Vedolizumab or placebo and given their first dose within 2 weeks of starting their SOC immunotherapy. Vedolizumab or placebo will be administered at Weeks 0, 2, 6, 14, and 22.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 298
Est. completion date December 1, 2026
Est. primary completion date November 1, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Signed informed consent prior to initiation of any study specific activities or procedures - Diagnosed with unresectable advanced stage III or metastatic stage IV malignancy - Planned for initiation of SOC immunotherapy and development of prognostic biomarker evidence that predisposes to ICI diarrhea/colitis risk - Ability to and willingness to adhere to the randomized treatment interventions (vedolizumab or placebo), administered intravenously Exclusion Criteria: - Condition(s) for which vedolizumab is contraindicated (e.g., hypersensitivity reaction, known allergic reaction to vedolizumab or its components) - Current or prior use of vedolizumab or prior immunotherapy exposure for cancer - Presence of inflammatory bowel disease (Crohn's disease, ulcerative colitis), indeterminate colitis, or microscopic colitis - Presence of ileostomy, colostomy, or short bowel syndrome - Presence of known luminal gastrointestinal metastases at baseline - Presence of significant pre-existing autoimmune disease (at investigator's discretion) - Presence of severe infection(s) or opportunistic infection(s) - Active enteric infection with viral, bacterial, or parasitic pathogens - Presence of untreated latent or active tuberculosis, or untreated chronic hepatitis B virus - Baseline ECOG status grade =3 - Pregnancy or lactation - Treatment with another investigational product within 8 weeks of randomization - Requirement for baseline anti-diarrheal treatment(s) (including but not limited to loperamide, diphenoxylate-atropine, octreotide, tincture of opium), anticholinergic drug(s), or opioid-based analgesic(s) used specifically for diarrhea control within 14 days of randomization - Any condition or diagnosis, that could in the opinion of the Qualified Investigator or delegate interfere with the participant's ability to comply with study instructions, might confound the interpretation of the study results, or put the participant at risk

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Vedolizumab
300 mg IV at weeks 0, 3, 6, 14, and 22
Placebo
300 mg IV at weeks 0, 3, 6, 14, and 22

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University of Calgary

Outcome

Type Measure Description Time frame Safety issue
Primary Hazard Ratio of Patients achieving ICI-related diarrhea and colitis-free survival a 6-months ICI-related diarrhea and colitis will be assessed using Common Terminology Criteria for Adverse Events (CTCAE), and a grade =2 will be considered an event. Start of immunotherapy therapy and for 6 months
Secondary Proportion of patients with histologically confirmed colitis-free survival at 6 months Colitis-free survival will be defined as CTCAE grade =2 based on a biopsy taken at time of patient meeting the primary endpoint or at 6 months. 6 months
Secondary Proportion of patients with severe diarrhea or colitis at 6 months Severe diarrhea or colitis will be defined as CTCAE grade =3 6 months
Secondary Hazard Ratio of patients with diarrhea or colitis after 6 months Diarrhea or colitis will be defined as CTCAE grade =2 6-12 months
Secondary Total average dose of checkpoint inhibitor therapy received within 6 and 12 months The total average dose of ICI therapy will be used 0 to 6 months; and 0 to 12 months
Secondary Proportion of participants who require temporary ICI discontinuation due to immune-related adverse events (irAEs) Temporary discontinuation of ICI therapy will be defined as any delay of 1-week or more resulting from an immune-related adverse event (irAE), as identified and graded using the Common Terminology Criteria for Adverse Events (CTCAE v5.0). 0 to 12 months
Secondary Proportion of participants who require permanent ICI discontinuation due to irAEs Permanent discontinuation of ICI therapy will be defined as stopping ICI therapy, and not restarting within the 1-year time window of the trial resulting from an immune-related adverse event (irAE), as identified and graded using the Common Terminology Criteria for Adverse Events (CTCAE v5.0). 0 to 12 months
Secondary Proportion of patients requiring rescue corticosteroids for ICI related diarrhea/colitis Any patient who receives rescue corticosteroids within the first 6 months or within the first 12 months will be considered an event. at 6-months and 12-months
Secondary Total average prednisone equivalent dose of rescue corticosteroids required The prednisone equivalent dose will be calculated using the following conversions:
Cortisone 5mg = Prednisone 1mg Hydrocortisone 4mg = Prednisone 1mg Prednisolone 1mg = Prednisone 1mg Methylprednisolone 0.8mg = Prednisone 1mg Dexamethasone 0.15mg = Prednisone 1mg
at 6-months and 12-months
Secondary Proportion of participants requiring all-cause hospitalization by Day +180 and Day +365 Chart review will be used to identify hospitalizations. at day 180 and 365
Secondary Proportion of participants requiring ICI-related diarrhea/colitis-specific hospitalization by Day +180 and Day +365 Chart review will be used to identify hospitalization and determine the cause of hospitalization. at day 180; at day 365
Secondary Mean change in the EuroQol EQ-5D instrument at Day +180 and Day +365 compared to baseline The EuroQol EQ-5D is a validated questionnaire for patients with inflammatory bowel disease. baseline to day 180; baseline to day 365
Secondary Overall survival (measured as death) at +180 and Day +365 compared to baseline All-cause mortality will be used to compare the survival rate of the therapy and placebo arms. The rates will be calculated for 6 months (defined at day 180) and 1-year (day 365). Day +180 and Day +365
Secondary Progression-free survival at 6- and 12-months, defined using the Response Evaluation Criteria in Solid Tumors (RECIST), v1.176 Progression-free survival will be defined using the Response Evaluation Criteria in Solid Tumors (RECIST), v1.176 At Day +180 and Day +365
Secondary Proportion of participants experiencing any adverse events (AEs) Adverse events will be defined as described in good clinical practice. At Day +180 and Day +365
Secondary Proportion of participants experiencing serious AEs Serious adverse events will be defined as described in good clinical practice. At Day +180 and Day +365
Secondary Proportion of participants experiencing other irAEs Adverse events will be defined as described in good clinical practice. Those that are immune related will be used for this outcome. At Day +180 and Day +365
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients